MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Axsome Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

105.25 1.09

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

102.62

Max

105.73

Galvenie mērījumi

By Trading Economics

Ienākumi

-10M

-75M

Pārdošana

14M

119M

EPS

-1.54

Peļņas marža

-63.075

Darbinieki

683

EBITDA

-10M

-71M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+66.84% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.1B

5.1B

Iepriekšējā atvēršanas cena

104.16

Iepriekšējā slēgšanas cena

105.25

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Axsome Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. apr. 23:54 UTC

Karstas akcijas

Stocks to Watch: Alphabet, Intel, AppFolio

2025. g. 24. apr. 23:51 UTC

Tirgus saruna

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025. g. 24. apr. 23:37 UTC

Top Ziņas

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025. g. 24. apr. 23:36 UTC

Top Ziņas

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025. g. 24. apr. 23:13 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025. g. 24. apr. 23:09 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025. g. 24. apr. 22:51 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025. g. 24. apr. 22:48 UTC

Top Ziņas

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025. g. 24. apr. 22:47 UTC

Tirgus saruna

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025. g. 24. apr. 22:38 UTC

Tirgus saruna
Peļņas

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025. g. 24. apr. 22:24 UTC

Tirgus saruna
Peļņas

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025. g. 24. apr. 22:23 UTC

Peļņas

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025. g. 24. apr. 22:09 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025. g. 24. apr. 22:00 UTC

Tirgus saruna
Peļņas

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025. g. 24. apr. 21:39 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025. g. 24. apr. 21:23 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025. g. 24. apr. 21:04 UTC

Peļņas

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025. g. 24. apr. 21:02 UTC

Peļņas

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Salīdzinājums

Cenas izmaiņa

Axsome Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

66.84% augšup

Prognoze 12 mēnešiem

Vidējais 175.87 USD  66.84%

Augstākais 216 USD

Zemākais 133 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Axsome Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

18

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

104.22 / 106.05Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Strong Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.